Services on Demand
Journal
Article
Spanish (pdf)
Article in xml format
Article references
Automatic translation
Send this article by e-mailIndicators
Cited by SciELO 
Access statistics
Related links
Similars in
SciELO
Share
Permalink
Gaceta Médica Boliviana
Print version ISSN 1012-2966On-line version ISSN 2227-3662
Abstract
RODRIGO LIRA, Gloria del Carmen; ITURRI-SOLIZ, J. Pablo and ROLLANO-PENALOZA, Oscar M.. Commercial salinomycin exhibits antiproliferative activity on three cancer cell lines under natural hypoxic conditions at 3 600 masl. Gac Med Bol [online]. 2025, vol.48, n.2, pp.70-78. Epub Dec 31, 2025. ISSN 1012-2966. https://doi.org/10.47993/gmb.v48i2.1038.
Salinomycin is a promising compound as an anticancer drug due to its antiproliferative action against cancer stem cells and its selective action, meaning it does not attack normal cells. Promising results have been shown for the ultrapure version of the compound, but the commercial version, which is currently used as a dietary supplement by veterinarians, has not yet been evaluated.
Objective:
to determine the antiproliferative activity of the ultrapure version and the commercial version of salinomycin on three cancer cell lines.
Methods:
a transversal in vitro experimental study was deployed to assess the antiproliferative effect of two versions of salinomycin on cancer cell lines Hela (cervical cancer cells), A549 (lung cancer cells), and MCF-7 (breast cancer cells). The MTT cytotoxicity assay was applied and the apoptotic cell morphology at 48h and 72h of treatment was evaluated. In addition, the amounts of salinomycin assimilated by the cell lines were measured at an altitude of 3 600 meters above sea level.
Results:
The results reveal that salinomycin in its commercial version has a good antiproliferative activity against cell lines of breast cancer (MCF-7), cervical cancer (HeLa) and lung cancer (A549), this activity is similar to the activity of the ultrapure compound and to that reported by published articles. The assimilation of salinomycin by the cell lines was quite low, observing that within 72 hours of incubation at the highest concentrations, 75% of the compound still remained. The results suggest that salinomycin in its commercial version, has the potential to become a low-cost drug.
Keywords : antineoplastic agents; uterine cervical neoplasms; breast neoplasms; lung neoplasms; salinomycin.
